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Abstract
Background  and  objectives:  Tramadol  hydrochloride  is  a  centrally-acting  synthetic  opioid  anal-
gesic binding  to  speciﬁc  opioid  receptors.  It  is  used  in  the  management  of  chronic  pain  and  is
recommended  as  ﬁrst  line  drug  in  the  treatment  of  postoperative  or  orthopedic  injury  induced
acute pain.  The  present  work  is  designed  to  prepare  and  evaluate  mucoadhesive  buccal  ﬁlm
of tramadol  hydrochloride  as  a  novel  form  of  prolonged  analgesia  for  patients  with  orthopedic
injuries.
Methods:  Buccal  ﬁlms  of  tramadol  hydrochloride  were  prepared  by  solvent  casting  method.  The
prepared ﬁlms  were  evaluated  for  the  various  evaluation  parameters  like  thickness,  surface  pH,
weight uniformity,  content  uniformity,  folding  endurance,  swelling  index,  in  vitro  drug  release
study, in  vitro  test  for  mucoadhesion  and  in  vivo  studies  (primary  mucosal  irritancy  test  and
analgesic activity).
Results:  All  the  formulations  exhibited  good  results  for  physicochemical  characterizations.  In
in vitro  drug  release  study  the  ﬁlms  exhibited  controlled  release  more  than  12  hours.  The  for-
mulation  BFT2  (containing  chitosan  and  PVP  K-90)  showed  no  irritant  effect  on  buccal  mucosa
and elicit  the  signiﬁcant  in  vivo  analgesic  activity  with  57.14%  analgesia  against  that  of  standard
(61.04%). It  was  concluded  that  the  mucoadhesive  ﬁlms  of  tramadol  hydrochloride  can  be  effec-
tively used  to  alleviate  the  severe  pain  of  orthopedic  injuries  with  prompt  onset  and  prolongeda  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  This  is  an
he  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-action.
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PALAVRAS-CHAVE
Mucoadesão;
Filme  bucal;
Tramadol;
Analgesia;
Edema;
Lesão  ortopédica
Filmes  bucais  mucoadesivos  de  tramadol  para  o  controle  eﬁcaz  da  dor
Resumo
Justiﬁcativa  e  objetivos:  O  cloridrato  de  tramadol  é  um  analgésico  opiáceo  de  ac¸ão  central  que
se liga  a  receptores  opiáceos  especíﬁcos.  É  usado  no  tratamento  de  dor  crônica  e  recomendado
como fármaco  de  primeira  linha  para  o  tratamento  no  pós-operatório  ou  em  dor  aguda  induzida
por lesão  ortopédica.  O  presente  estudo  visa  preparar  e  avaliar  o  ﬁlme  bucal  mucoadesivo
de cloridrato  de  tramadol  como  uma  nova  forma  de  analgesia  prolongada  para  pacientes  com
lesões ortopédicas.
Método:  Filmes  bucais  de  cloridrato  de  tramadol  foram  preparados  pelo  método  de  evaporac¸ão
de solvente.  Os  ﬁlmes  preparados  foram  avaliados  para  os  vários  parâmetros  de  avaliac¸ão  como
espessura,  pH  da  superfície,  uniformidade  do  peso,  uniformidade  do  conteúdo,  resistência  a
dobras, índice  de  intumescimento,  estudo  de  liberac¸ão  da  droga  in  vitro,  teste  in  vitro  para
mucoadesão  e  estudos  in  vivo  (teste  de  irritac¸ão  da  mucosa  primária  e  atividade  analgésica).
Resultados:  Todas  as  formulac¸ões  apresentaram  bons  resultados  para  caracterizac¸ões  físico-
químicas.  Em  estudo  de  libertac¸ão  de  droga  in  vitro,  os  ﬁlmes  exibiram  liberac¸ão  controlada
mais de  12  horas.  A  formulac¸ão  de  BFT2  (contendo  quitosana  e  PVP  K-90)  não  mostrou  efeito  irri-
tante sobre  a  mucosa  bucal  e  provocou  uma  atividade  analgésica  signiﬁcativa  in  vivo  com  57,14%
de analgesia  versus  a  do  padrão  (61,04%).  Concluiu-se  que  os  ﬁlmes  mucoadesivos  de  cloridrato
de tramadol  podem  ser  usados  eﬁcazmente  para  aliviar  a  dor  intensa  de  lesões  ortopédicas  com
início rápido  e  ac¸ão  prolongada.
© 2016  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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uccal  drug  administration  is  very  widely  accepted  route  of
dministration  for  potent  medicines  for  the  clinical  condi-
ions  which  is  associated  with  severe  pain  and  discomfort.1
enerally  orthopedic  patients  suffering  from  disorders
f  the  skeletal  system  and  associated  muscles,  joints,
nd  ligaments  needs  constant  and  prolonged  drug  deliv-
ry  for  effective  management  of  therapeutic  condition.2
uccoadhesive  drug  delivery  avoids  the  destruction  by  gas-
rointestinal  contents  or  hepatic  ﬁrst-pass  inactivation  of
rug  and  ensures  intimate  contact  of  drug  to  the  biological
ystem  for  better  drug  absorption.3,4
Generally  post-operative  pain  is  effectively  managed  by
pioid  analgesic,  semisynthetic  opioids,  neuroleptic  anal-
esic  and  potent  NSAIDS.  But  immediate  after  surgery  many
 time’s  even  very  strong  analgesics  cannot  effectively  man-
ge  the  pain.  When  the  effect  of  general  anesthesia  subsides
generally  after  6--12  h  after  surgery)  patients  feels  a great
ain  which  might  not  be  managed  by  any  means  and  many
imes  are  intolerable.  Therefore,  the  present  study  was
onducted  to  explore  the  feasibility  and  effectiveness  of
uccal  mucoadhesive  drug  delivery  of  tramadol  as  an  effec-
ive  alternative  of  NSAIDs  in  relieving  pain  after  surgery
r  orthopedic  injury.  In  an  attempt  to  reduce  the  rela-
ively  high  incidence  of  serious  adverse  effects  associated
ith  the  systemic  use  of  NSAIDs,  a  growing  number  of  topi-
al  formulations  of  these  drugs  have  become  commercially
5Please  cite  this  article  in  press  as:  Li  X-Q,  et  al.  Mucoadhesive
Rev  Bras  Anestesiol.  2016.  http://dx.doi.org/10.1016/j.bjane.
vailable. The  present  work  is  designed  to  prepare  and
valuate  mucoadhesive  buccal  ﬁlm  of  tramadol  hydrochlo-
ide  as  a  novel  form  of  prolonged  analgesia  for  patients  with
rthopedic  injuries.
r
P
s
tTramadol  hydrochloride  is  a centrally-acting  synthetic
pioid  analgesic  binding  to  speciﬁc  opioid  receptors.  It  is
 non-selective,  pure  agonist  at  mu,  delta  and  kappa  opioid
eceptors  with  a  higher  afﬁnity  for  the  mu  receptor.2,6 Tra-
adol  HCl  is  freely  soluble  in  water,  and  readily  absorbed
ollowing  oral  administration.  The  systemic  bioavailability
f  tramadol  hydrochloride  is  approximately  68%  after  oral
dministration.  Tramadol  HCl  is  a  centrally  acting  analgesic
sed  in  management  of  chronic  pain  and  is  recommended
s  ﬁrst  line  drug  treatment  of  orthopedic  injury  to  produce
dequate  pain  relief.  The  half-life  of  a  drug  is  about  5.5  h
nd  the  usual  oral  dosage  regimen  is  50--100  mg  every  4--6  h
ith  a  maximum  dosage  of  400  mg/day.7
ethods
hitosan,  PVP  K-90  and  PVP  K-70  were  purchased  from
igma--Aldrich.  All  other  chemicals  used  were  of  analytical
rades.
reparations  of  buccal  ﬁlm  of  tramadol
uccal  ﬁlm  of  tramadol  hydrochloride  were  prepared  by
olvent  casting  methods  using  two  different  grades  of  PVP
-90  and  PVP  K-70  and  chitosan  as  mucoadhesive  polymers.
olymeric  solution  of  chitosan  was  prepared  by  dissolving
hitosan  in  acetic  acid  in  distilled  water  with  constant  stir- buccal  ﬁlms  of  tramadol  for  effective  pain  management.
2015.08.016
ing.  PVP  was  added  to  the  solution  of  chitosan  with  stirring.
ropylene  glycol  (5%,  V/V)  was  added  as  plasticizer.  This
olution  was  kept  overnight  to  ensure  clear  bubble  free  solu-
ion.  The  weighed  quantity  of  tramadol  HCl  was  added  to
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Mucoadhesive  buccal  ﬁlms  of  tramadol  for  effective  pain  ma
polymeric  solution  and  the  solution  was  poured  into  a glass
Petri  dish  having  9.5  cm  diameter.  The  Petri  dishes  were  kept
on  ﬂat  surface  and  covered  by  inverted  funnel  to  allow  con-
trolled  evaporation  of  solvent  at  40 ◦C  till  a  ﬂexible  ﬁlm  was
formed.  Dried  ﬁlms  were  carefully  removed,  checked  for  any
imperfections  or  air  bubbles  and  cut  into  ﬁlms  of  10  mm  in
diameter.8,9
Thickness  and  weight  uniformity
A  standard  screw  gauge  was  used  to  measure  the  thickness
of  three  randomly  selected  buccal  ﬁlms  from  each  batch.
Weight  uniformity  of  ﬁlm  was  tested  by  taking  weight  of  ﬁve
ﬁlms  of  sizes  10  mm  diameter  from  each  batch  and  weigh
individually  on  electronic  balance  and  the  average  weight
was  calculated.10
Content  uniformity
Drug  content  uniformity  was  determined  by  dissolving
the  buccal  ﬁlm  (10  mm  in  diameter)  from  each  batch
by  homogenization  in  100  mL  of  an  isotonic  phosphate
buffer  (pH  6.8)  for  6  h  under  occasional  shaking.  The  drug
content  was  then  determined  after  proper  dilution  and
measured  the  absorbance  at  271  nm  using  a  UV--visible
spectrophotometer.11
Folding  endurance
Randomly  selected  three  ﬁlms  from  each  batch  were  taken
to  measure  the  folding  endurance.  The  ﬁlms  were  repeat-
edly  folded  at  the  same  place  till  it  broke.  The  ﬁlms
folded  up  to  300  times  manually  was  considered  satisfac-
tory  value.12 The  number  of  times  of  ﬁlm  could  be  folded
at  the  same  place  without  breaking  gave  the  value  of  the
folding  endurance.
Surface  pH
Buccal  ﬁlms  were  left  to  swell  for  1  h  on  the  surface  of  the
agar  plate,  prepared  by  dissolving  2%  (w/v)  agar  in  warmed
isotonic  phosphate  buffer  of  pH  6.8  under  stirring  and  then
poured  the  solution  into  the  petridish  allowed  to  stand  till
gelling  at  room  temperature.  The  surface  pH  was  measured
by  means  of  pH  paper  placed  on  the  surface  of  the  swollen
ﬁlm.13,14
Swelling  index
The  water  uptake  was  determined  gravimetrically.  The  dried
ﬁlms  ﬁxed  to  stainless  steel  support  were  immersed  in  a
beaker  containing  25  mL  distilled  water  at  room  tempera-Please  cite  this  article  in  press  as:  Li  X-Q,  et  al.  Mucoadhesive
Rev  Bras  Anestesiol.  2016.  http://dx.doi.org/10.1016/j.bjane.
ture.  At  speciﬁc  intervals  up  to  3  h,  the  swollen  sample  with
the  pre-weighed  mesh  were  weighed  after  removal  of  excess
surface  water  by  light  blotting  with  a  ﬁlter  paper.  The  exper-
iment  was  discontinued  when  the  ﬁlms  begin  to  disintegrate
T
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ement  3
r  dissolve.15 To  quantify  the  swelling  process,  the  swelling
ndex  percentage  was  calculated  as  follows:
welling  index  %  =
(
Ws −  Wd
Wd
)
×  100
here  Wd is  the  weight  of  the  dried  polymer  ﬁlm  and  Ws is
he  weight  after  swelling.
n  vitro  release  study
n  vitro  drug  release  study  was  carried  out  by  using  modiﬁed
issolution  test  apparatus  type  1  (eight-station  dissolution
pparatus).  The  dissolution  medium,  50  mL  IPB,  pH  6.8,
ere  maintained  at  37  ±  0.50 ◦C  and  it  was  kept  in  a  glass
eaker  placed  inside  the  dissolution  ﬂask.  The  ﬁlm  was
ttached  to  end  of  the  shaft  (without  basket)  with  the  help
f  cyanoacrylate  adhesive,  which  was  rotated  at  50  rpm.16
liquots  of  samples  (2  mL)  were  withdrawn  at  the  intervals
f  1,  2,  3,  4,  5,  6  and  7 h  and  ﬁltered  using  Whatman  ﬁl-
er  paper  No.  1.  The  withdrawals  were  compensated  using
qual  volumes  of  IPB  kept  at  the  same  temperature.  The
oncentration  of  drug  released  in  the  medium  was  measured
pectrophotometrically  at  271  nm  after  suitable  dilution
ith  the  dissolution  medium.
n  vitro  mucoadhesion  test
he  in  vitro  mucoadhesion  time  was  determined  by  using  a
odiﬁed  USP  disintegration  apparatus.  800  mL  of  phosphate
uffer  of  pH  6.8  (IPB)  maintained  at  37  ±  0.50 ◦C  were  used
s  disintegration  medium.  A  piece  of  porcine  buccal  mucosa,
 cm  length  was  taken  for  the  study.  The  buccal  mucosa  was
ttached  to  a  rectangular  glass  piece  using  cyanoacrylate
dhesive  from  non-mucosal  surface.  The  mucoadhesive  ﬁlm
as  hydrated  from  one  surface  using  pH  6.8  IPB  and  then  the
ydrated  surface  was  brought  in  contact  with  the  mucosal
embrane.  The  glass  slab  was  vertically  ﬁxed  to  the  appa-
atus  and  allowed  to  move  up  and  down  so  that  the  ﬁlm  was
ompletely  immersed  in  the  buffer  solution  at  the  lowest
oint  and  was  out  at  the  highest  point.17 The  time  neces-
ary  for  complete  detachment  of  the  ﬁlm  from  the  mucosal
urface  was  observed  and  recorded  (n  =  3).
n  vivo  study
he  healthy  male  Wistar  rats  (200--250  g)  were  used  for  the
tudy.  The  rats  were  kept  in  cages  in  standard  environ-
ental  conditions  of  light  and  temperature.  The  rats  were
llowed  free  access  to  drinking  water  and  standard  diet.
he  protocols  of  the  animal  study  were  approved  by  the
nstitutional  Animal  Care  and  Use  Committee  of  Zhejiang
niversity,  Hangzhou  (approval  ref  no.  109.  10/08/2014);
nd  was  carried  out  in  compliance  with  the  Directive.
rimary  mucosal  irritancy  studies buccal  ﬁlms  of  tramadol  for  effective  pain  management.
2015.08.016
he  irritant  effect  or  any  chance  of  edema  with  the  use
f  buccal  ﬁlms  was  assessed  by  primary  mucosal  irritancy
est.  The  healthy  male  rats  (200--250  g)  were  divided  into
hree  groups  of  three  rats  each.  The  non-medicated  ﬁlm
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Table  1  Formulations  of  buccal  ﬁlms  of  tramadol  hydrochloride.
Formulation  code  Chitosan  %
(w/w)
PVP  K-90
(mg)
PVP  K-70
(mg)
Propylene  glycol
(%)
Tramadol
(mg)
BFT1  1  50  --  5  500
BFT2 1  100  -- 5  500
BFT3 1.5 50  -- 5  500
BFT4 1.5  100  --  5  500
BFT5 1  --  50  5  500
w
t
g
t
(
t
a
a
I
M
e
m
ﬁ
s
b
a
t
o
t
f
r
S
R
t
o
(
R
B
s
P
w
p
m
i
f
T
b
s
t
a
6
t
o
w
a
f
o
t
t
l
t
P
s
1
h
s
i
t
tBFT6 1.5  --  
as  applied  to  oral  mucosa  (of  urethane  anesthetized  rats)
o  the  group  I  (control)  using  an  adhesive  tape  USP.  To  the
roup  II  (test)  transmucosal  patch  formulation  BFT2  (con-
aining  chitosan  and  PVP  K-90)  was  applied.  To  the  group  III
standard)  0.8%  v/v  aqueous  solution  of  formaldehyde  (irri-
ant)  was  applied.  The  application  sites  were  observed  for
ny  erythema  and  edema  on  the  mucosal  surface  for  2  days
fter  application  and  the  scoring  was  done  (Table  1).
n  vivo  analgesic  activity
al  albino  rats  were  divided  in  three  groups  of  six  rats
ach.  The  ﬁrst  group  served  as  control  and  it  received  non-
edicated  buccal  ﬁlms.  The  test  group  II  received  buccal
lms  (BFT2,  50  g·kg−1 body  mass).  The  third  group  received
tandard  (transmucosal  gel  of  fentanyl  citrate,  10  g·kg−1
ody  mass).  Three  hours  after  treatment,  0.6%  (V/V)  acetic
cid  solution  (10  mL·kg−1)  was  injected  to  rats  intraperi-
oneally.  Total  number  of  writhes,  which  was  a  parameter
f  chemically  induced  pain  (i.e.,  constriction  of  abdomen,
urning  of  trunk  and  extension  of  hind  legs),  was  counted
or  20  min  The  analgesic  effect  was  expressed  as  percent
eduction  of  writhes  in  comparison  with  the  control.
tatistical  analysis
esults  were  expressed  as  mean  values  ±  standard  devia-
ions.  Statistical  analysis  was  carried  out  using  the  analysis
f  variance  (ANOVA).  A  probability  value  less  than  0.05
p  < 0.05)  was  considered  to  be  a  signiﬁcant  value.Please  cite  this  article  in  press  as:  Li  X-Q,  et  al.  Mucoadhesive
Rev  Bras  Anestesiol.  2016.  http://dx.doi.org/10.1016/j.bjane.
esults
uccal  ﬁlms  of  tramadol  hydrochloride  were  prepared  by
olvent  casting  method  by  using  Chitosan  PVP  K-70  and
f
i
t
r
Table  2  Physicochemical  characteristics  of  prepared  buccal  ﬁlms
Buccal  ﬁlm
code
Thickness  (mm)  Surface  pH  Weigh
uniform
(mg
BFT1  0.24  ±  0.04  6.82  ±  0.28  36.6  ±  1
BFT2 0.26  ±  0.03  6.40  ±  0.16  35.6  ±  1
BFT3 0.31  ±  0.03  6.44  ±  0.09  31.1  ±  1
BFT4 0.32  ±  0.02  6.59  ±  0.12  39.7  ±  1
BFT5 0.49  ±  0.06  6.52  ±  0.44  46.2  ±  1
BFT6 0.54  ±  0.02  6.53  ±  0.23  50.1  ±  1100  5  500
VP  K-90  as  mucoadhesive  polymers.  The  prepared  ﬁlms
ere  evaluated  for  the  various  physicochemical  evaluation
arameters  like  thickness,  surface  pH,  weight  unifor-
ity,  content  uniformity,  folding  endurance  and  swelling
ndex  (Table  2).  Thickness  of  all  six  formulations  was
ound  to  be  in  the  range  of  0.24  ±  0.04  to  0.54  ±  0.02  mm
he  all  prepared  formulation  of  tramadol  hydrochloride
uccal  ﬁlm  showed  the  pH  range  within  the  range  of
alivary  pH  i.e.  6.32--6.82.  The  observed  surface  pH  of
he  formulation  BFT1,  BFT2,  BFT3,  BFT4,  BFT5  and  BFT6
re  6.82  ±  0.28,  6.40  ±  0.16,  6.44  ±  0.09,  6.59  ±  0.12,
.52  ±  0.44,  6.53  ±  0.23  respectively.  The  result  of  ﬁlm
hickness  showed  that  there  was  no  signiﬁcant  difference
f  surface  pH  in  all  the  formulation.  The  folding  endurance
as  measured  manually,  by  folding  the  ﬁlm  repeatedly  at
 point  till  it  broke.  The  number  of  times  of  ﬁlm  could  be
olded  at  the  same  place  without  breaking  gave  the  value
f  the  folding  endurance.  Hence  the  breaking  time  was
aken  as  the  end  point.  The  folding  endurance  was  found
o  be  highest  for  formulation  BFT6  (298  ±  5.211)  and  the
owest  for  formulation  BFT1  (238  ±  4.211).  It  was  found  that
he  folding  endurance  was  increased  with  the  addition  of
VP  with  increased  concentration  of  chitosan.18,19 Percent
welling  of  buccal  ﬁlms  were  found  to  be  in  the  range  of
7.40  ±  0.28  to  24.66  ±  1.50.  It  was  concluded  that  more
ydrophilic  nature  of  polymer  in  BFT2  resulted  in  maximum
welling  as  compared  to  the  other  formulations.
In  vitro  drug  release  study  was  carried  out  by  using  mod-
ﬁed  dissolution  test  apparatus  (Fig.  1).  The  study  revealed
hat  the  drug  release  was  dependent  on  the  concentra-
ion  and  different  grades  of  polymers  used.  Among  all  the buccal  ﬁlms  of  tramadol  for  effective  pain  management.
2015.08.016
ormulations  of  buccal  ﬁlms  formulation  BFT2  showed  max-
mum  drug  release  at  the  end  of  12  h.  In  vitro  mucoadhesion
est  was  performed  by  using  modiﬁed  disintegrating  appa-
atus.  Results  of  in  vitro  mucoadhesion  test  showed  that
 of  tramadol  HCl.
t
ity
)
Folding
endurance
Drug
content
(%)
Swelling  %
after  6  h
.53  238  ±  4.211  96.66  ±  1.2  17.40  ±  0.28
.52  244  ±  5.311  92.14  ±  1.1  24.66  ±  1.50
.64  253  ±  6.211  95.51  ±  3.4  22.11  ±  1.08
.60  254  ±  2.241  93.81  ±  1.0  23.66  ±  1.12
.38  279  ±  8.111  91.56  ±  2.5  17.66  ±  1.52
.32  298  ±  5.211  95.87  ±  2.1  18.33  ±  1.61
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Table  3  Primary  mucosal  irritation  test  of  transmucosal  mucoadhesive  buccal  ﬁlms  of  tramadol.
Rat  no.  Control  group  I  Test  (BFT2)  group  II  Standard  irritant  group  III
Erythemaa Edemab Erythemaa Edemab Erythemaa Edemab
1  1  0  1  1  3  2
2 0  1  0  1  3  2
3 0  1  0  0  3  1
Average ±  S.D  0.34  ±  0.58c 0.67  ±  0.58c 0.34  ±  0.58c 0.67  ±  0.58c 3  ±  0  1.67  ±  0.50
a Erythema scale: 0, none; 1, slight; 2, well deﬁned; 3, moderate; and 4, scar formation.
b Edema scale: 0, none; 1, slight; 2, well deﬁned; 3, moderate; and 4, severe; n = 3.
c p < 0.05, signiﬁcant compared with formalin.
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Figure  1  In  vitro  drug  release  study  of  buccal  ﬁlms  of  tra-
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dmadol hydrochloride  in  phosphate  buffer  of  pH  6.8.
formulation  BFT6  with  higher  concentration  of  chitosan
showed  the  maximum  mucoadhesion  property  as  compared
to  others.20,21 Whereas  BFT2  had  the  least  mucoadhesion
property,  which  might  be  due  to  hydrophilic  nature  of  PVP
K-90  which  loosen  the  bond  strength  from  the  mucosal
area.
Formulation  BFT2  was  subjected  to  in  vivo  studies  for  pri-
mary  mucosal  irritancy  test  and  analgesic  activity.  The  BFT2
ﬁlms  were  found  to  be  non-irritant  in  the  primary  mucosalPlease  cite  this  article  in  press  as:  Li  X-Q,  et  al.  Mucoadhesive
Rev  Bras  Anestesiol.  2016.  http://dx.doi.org/10.1016/j.bjane.
irritation  test  (Table  3).  The  formulation  BFT2  showed  signif-
icantly  good  in  vivo  analgesic  activity  with  57.14%  analgesia
against  that  of  standard  which  showed  61.04%  analgesia
(Table  4).
t
r
i
s
Table  4  In  vivo  analgesic  activity  of  transmucosal  mucoadhesive
Drug Oral  dosea
(g·kg−1)
Control  (blank  ﬁlms)  --  
Fentanyl citrate  (standard)  10  
BFT2 20  
a Dose equimolar to the parent drug calculated on the basis of drug c
b Mean ± SEM, n = 6.
c p < 0.05 vs. control.iscussion
ucoadhesion  is  one  of  the  most  widely  investigated
pproaches  in  delivering  the  drugs  for  quick  onset  of  action
nd  improved  bioavailability.  The  buccal  mucosa  being  rich
n  vasculature  provides  a  very  good  platform  for  delivering
he  drug  directly  to  the  systemic  circulation.  The  dosage
equirement  is  very  less  as  compared  to  that  of  oral  drug
elivery.  In  orthopedic  patients  the  acute  pain  is  many  a
imes  is  to  be  dealt  immediately  with  high  efﬁcacy.  And  for
he  same  buccal  mucoadhesive  patches  are  considered  to  be
he  best  approach.21--24 The  mucoadhesive  buccal  patches  of
nalgesics  have  been  investigated  inclusive  of  tramadol.25--27
ral  Transmucosal  Fentanyl  Citrate  (OTFC)  provides  the
apid-onset  opioids  and  a  short  duration  of  analgesia.  Exten-
ive  researches  have  been  done  on  the  transmucosal  drug
elivery  system  of  fentanyl  for  buccal,  sublingual  and  nasal
ucosal  delivery.28--31
The  various  alternative  dosage  forms  of  tramadol
ave  been  investigated  for  improving  the  efﬁcacy  of  the
reatment.32--34 In  some  previous  studies  also  the  mucoad-
esive  dosage  forms  have  been  developed  for  tramadol.27,34
In  the  present  study,  as  compared  to  other  formulations
FT2  (containing  chitosan  and  PVP  K-90)  showed  increased
urface  wetting  and  water  penetration  which  resulted  in
ood  dissolution  proﬁle.  On  the  other  hand,  formulation
FT6  (containing  chitosan  and  PVP  K-70)  showed  minimum
rug  release;  might  be  due  to  more  concentration  of  chi- buccal  ﬁlms  of  tramadol  for  effective  pain  management.
2015.08.016
osan  which  being  less  water  soluble  retarded  the  drug
elease.  Results  of  in  vitro  release  study  indicated  that  vary-
ng  concentration  of  chitosan  did  not  affect  the  drug  release
igniﬁcantly.
 buccal  ﬁlms  of  ﬁlms  of  tramadol.
Analgesic  activity
N◦ of  writhesb Analgesia%
77  ±  4  --
30  ±  1c 61.04
33  ±  2c 57.14
ontents.
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BFT2  showed  excellent  analgesic  activity  with  no
rritation  on  the  mucosa.  The  analgesic  activity  was  very
uch  comparable  to  the  standard  oral  mucoadhesive  for-
ulation  of  fentanyl  citrate  which  is  a  very  well  known
nalgesic  opioid  with  rapid-onset  and  a  short  duration  of
nalgesia.  So  not  only  the  rapid  onset  of  action  but  also
he  prolonged  release  (as  indicated  by  in  vitro  release  data)
Fig.  1)  can  be  achieved  with  the  present  formulation  of
ramadol.
ummary
he  results  of  the  study  show  that  therapeutic  levels  of  tra-
adol  can  be  delivered  through  buccal  route.  The  present
tudy  concludes  that  these  erodible  mucoadhesive  buccal
lms  containing  tramadol  can  be  very  promising  for  effec-
ive  doses  to  systemic  circulation  in  patients  of  orthopedic
njuries.  Films  exhibited  controlled  release  over  more  than
0  h  with  no  irritation  on  mucosa.  The  ﬁlms  showed  compa-
able  analgesic  effect  in  vivo  studies.  Thus  these  ﬁlms  can
e  selected  for  the  development  of  buccal  ﬁlm  for  effective
herapeutic  uses.
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